- |||||||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Feb 4, 2019 P3, N=212, Active, not recruiting, Trial primary completion date: Oct 2017 --> Mar 2018
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Enrollment change: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Jul 6, 2018 P1, N=38, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2018 Recruiting --> Active, not recruiting | N=60 --> 38
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Oct 12, 2017 P=N/A, N=100, Active, not recruiting, Recruiting --> Active, not recruiting | N=450 --> 600 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 2, 2016 P3, N=445, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed, Trial primary completion date, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Jul 28, 2016 P2, N=112, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016
- |||||||||| Ukoniq (umbralisib) / TG Therap
Enrollment closed, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 8, 2015 P1, N=30, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
|